Clinical Trials Directory

Trials / Completed

CompletedNCT00518479

Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
42 (actual)
Sponsor
University of Leeds · Academic / Other
Sex
All
Age
25 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Uncontrolled high blood pressure can cause heart muscle 'thickening', and this increases the likelihood of complications and death. The high blood pressure explains some but not all of this increase in heart size. This study will investigate the other causes, and will measure the heart muscle 'thickness' very accurately using the latest and most accurate technique called cardiac magnetic resonance imaging (MRI). The best way to treat this heart thickening remains to be determined. We hope to be able to show that by specifically targeting the cause of heart muscle thickening we can reduce its occurrence more effectively than by other standard means of blood pressure treatment

Conditions

Interventions

TypeNameDescription
DRUGBendroflumethiazide 2.5mg OD; Amlodipine 10mg OD
DRUGValsartan 160mg OD; Moxonidine 400mcg OD

Timeline

Start date
2003-09-01
Completion
2004-04-01
First posted
2007-08-20
Last updated
2012-08-16

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT00518479. Inclusion in this directory is not an endorsement.

Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression (NCT00518479) · Clinical Trials Directory